Physician profile
Olatz Ormazabal
NPI 1255770699
$1,177.23
in general payments reported to CMS, 2019-2025
18 companies · $27.97 in 2025
The $27.97 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $389 · 2021: $227 · 2022: $20.29 · 2024: $125 · 2025: $27.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $256.02 | 2019-2024 | Injectafer |
| Glaxosmithkline, LLC. | $139.51 | 2019-2022 | |
| Amgen INC. | $108.87 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.81 | 2019-2021 | |
| Pfizer INC. | $88.50 | 2019-2020 | |
| Novo Nordisk INC | $76.09 | 2019-2021 | |
| Lilly USA, LLC | $65.67 | 2019-2020 | |
| Abbvie INC. | $53.70 | 2021 | |
| Amarin Pharma, INC. | $52.65 | 2020 | |
| Astellas Pharma US INC | $50.76 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $40.41 | 2021 | |
| American Regent | $27.97 | 2025 | Injectafer |
| Sanofi-Aventis U.S. LLC | $24.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.99 | 2019 | |
| Allergan, INC. | $23.91 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $22.47 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.51 | 2019 | |
| Mylan Specialty L.P. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olatz Ormazabal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.